eXoZymes Inc. Common Stock EXOZ Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| $4.25M+96.3% | $3.71M+98.4% | $3.23M+89.8% | $2.73M+172% | $2.17M— | ||
| $5.9M+25.3% | $6.01M+47.9% | $5.78M+78.7% | $5.36M+97.9% | $4.71M— | ||
| $3.85M+40.0% | $3.64M+43.8% | $3.39M+71.6% | $3.09M+99.6% | $2.75M— | ||
| $1.19M-17.7% | $1.44M+23.5% | $1.49M+56.7% | $1.52M+96.6% | $1.44M— | ||
| $10.15M+47.7% | $9.72M+63.8% | $9M+82.5% | $8.09M+118% | $6.87M— | ||
| -$10.15M-47.7% | -$9.72M-63.8% | -$9M-82.5% | -$8.09M-118% | -$6.87M— | ||
| $281.5K+151% | $362.09K+367% | $233.23K+213% | $218.69K— | $112.36K— | ||
| —— | —— | —— | —— | —— | ||
| -$9.78M-45.7% | -$9.26M-58.1% | -$8.34M-64.2% | -$7.71M-95.5% | -$6.71M— | ||
| —— | -$105.21K— | —— | —— | —— | ||
| -$9.67M-44.2% | -$9.16M-56.3% | -$8.34M-62.8% | -$7.71M-93.3% | -$6.71M-139% | ||
| -$1.14-18.8% | -$1.08-20.0% | -$1.02-22.9% | -$1.02-59.4% | -$0.96— | ||
| -$1.14-18.8% | -$1.08-20.0% | -$1.02-22.9% | -$1.02-59.4% | -$0.96— | ||
| 33.6M+22.5% | 33.5M+32.4% | 31.7M+26.8% | 29.6M+18.2% | 27.4M— | ||
| 33.6M+22.5% | 33.5M+32.4% | 31.7M+26.8% | 29.6M+18.2% | 27.4M— | ||
| $281.5K+63.7% | $362.09K+367% | $382.09K+614% | $278.26K+1,036% | $171.92K+229,125% | ||
| $80.98K+34.8% | $95.99K+148% | $84.72K+143% | $92.2K+252% | $60.08K— | ||
| $779.09K+71.8% | $836.07K+154% | $816.22K+198% | $658.98K+82.1% | $453.52K— | ||
| —— | —— | —— | —— | —— | ||
| -$10.15M-47.7% | -$9.72M-63.8% | -$9M-82.5% | -$8.09M-118% | -$6.87M— | ||
| -$9.86M-49.4% | -$9.43M-66.4% | -$8.72M-86.6% | -$7.81M-125% | -$6.6M— | ||
| -$9.86M-49.4% | -$9.43M-66.4% | -$8.72M-86.6% | -$7.81M-125% | -$6.6M— | ||
| -$10.15M-47.7% | -$9.72M-63.8% | -$9M-82.5% | -$8.09M-118% | -$6.87M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is eXoZymes Inc. Common Stock's revenue?
- eXoZymes Inc. Common Stock (EXOZ) generated $70.1K in revenue over the trailing twelve months.
- Is eXoZymes Inc. Common Stock profitable?
- eXoZymes Inc. Common Stock is not currently profitable: it reported a net loss of $9.7M over the trailing twelve months, a -2909.1% net margin.
- What is eXoZymes Inc. Common Stock's earnings per share?
- eXoZymes Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.14.
- Where does eXoZymes Inc. Common Stock's income statement data come from?
- Every line is extracted from eXoZymes Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
